UBE2N Decline Tracks MASLD-to-MASH Progression; Enzyme Restoration Cuts Mouse Liver Injury via Mitophagy

Researchers measured UBE2N protein in human liver biopsies and mouse models of MASLD, documenting progressive loss that paralleled mitochondrial damage and impaired mitophagy. When UBE2N was overexpressed or pharmacologically supported in diet-induced MASH mice, autophagic removal of dysfunctional mitochondria increased, lowering hepatic triglycerides by roughly 35% and collagen deposition by 40% within eight weeks. These functional gains occurred without altering body weight or insulin sensitivity, pointing to a mitochondria-specific protective mechanism rather than broad metabolic reprogramming. The work extends prior observations that defective mitophagy drives MASH progression, yet it supplies the first direct enzymatic node—UBE2N—that declines in lockstep with human disease stage. Existing MASH drugs such as resmetirom act on thyroid hormone signaling; a UBE2N-targeted approach could complement them by addressing a downstream mitochondrial lesion that current therapies leave untouched. Translation hurdles remain substantial. Human UBE2N expression varies by genotype and comorbidities, and no selective small-molecule activator yet exists. Organoid and non-human primate studies are required before any candidate enters phase I.